GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (CHIX:BSLNz) » Definitions » EV-to-FCF

Basilea Pharmaceutica (CHIX:BSLNZ) EV-to-FCF : 67.12 (As of Mar. 29, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Basilea Pharmaceutica EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Basilea Pharmaceutica's Enterprise Value is CHF613.2 Mil. Basilea Pharmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was CHF9.1 Mil. Therefore, Basilea Pharmaceutica's EV-to-FCF for today is 67.12.

The historical rank and industry rank for Basilea Pharmaceutica's EV-to-FCF or its related term are showing as below:

CHIX:BSLNz' s EV-to-FCF Range Over the Past 10 Years
Min: -19.67   Med: -8.22   Max: 197.24
Current: 68.25

During the past 13 years, the highest EV-to-FCF of Basilea Pharmaceutica was 197.24. The lowest was -19.67. And the median was -8.22.

CHIX:BSLNz's EV-to-FCF is ranked worse than
86.89% of 427 companies
in the Biotechnology industry
Industry Median: 2.91 vs CHIX:BSLNz: 68.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-29), Basilea Pharmaceutica's stock price is CHF46.55. Basilea Pharmaceutica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was CHF0.860. Therefore, Basilea Pharmaceutica's PE Ratio (TTM) for today is 54.13.


Basilea Pharmaceutica EV-to-FCF Historical Data

The historical data trend for Basilea Pharmaceutica's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica EV-to-FCF Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.94 -11.67 -16.87 173.14 37.27

Basilea Pharmaceutica Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 173.14 - 37.27 -

Competitive Comparison of Basilea Pharmaceutica's EV-to-FCF

For the Biotechnology subindustry, Basilea Pharmaceutica's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's EV-to-FCF falls into.


;
;

Basilea Pharmaceutica EV-to-FCF Calculation

Basilea Pharmaceutica's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=613.206/9.136
=67.12

Basilea Pharmaceutica's current Enterprise Value is CHF613.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was CHF9.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Basilea Pharmaceutica  (CHIX:BSLNz) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Basilea Pharmaceutica's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=46.55/0.860
=54.13

Basilea Pharmaceutica's share price for today is CHF46.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was CHF0.860.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Basilea Pharmaceutica EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica Business Description

Traded in Other Exchanges
Address
Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica Headlines

No Headlines